Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Safety Outcomes of Patients Admitted to Different Specialty Wards: The Prospective, Multi-center, Controlled SISIFO Study.

Journal of patient safety·2026
Same author

Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention.

Internal and emergency medicine·2026
Same author

Prescribing patterns and clinician preferences for direct oral anticoagulant use in unusual site venous thromboembolism: a cross-sectional analysis from the Direct oral anticoagulants in Unusual Site venous Thromboembolism (DUST) study.

Research and practice in thrombosis and haemostasis·2026
Same author

Clinical and patient-reported outcomes after drug-coated balloon angioplasty for femoropopliteal peripheral artery disease.

VASA. Zeitschrift fur Gefasskrankheiten·2026
Same author

Exploring Italian nursing staff in anticoagulation clinics: a cluster-based description of current practice, nurse self-efficacy, job satisfaction, and interprofessional collaboration.

Internal and emergency medicine·2026
Same author

Endovascular reperfusion strategies for pregnancy-related pulmonary embolism: a systematic review.

Journal of thrombosis and thrombolysis·2026
Same journal

When Rosai-Dorfman meets autoimmunity.

Internal and emergency medicine·2026
Same journal

Hypocholesterolemia as a predictor of mortality in infective endocarditis.

Internal and emergency medicine·2026
Same journal

Correction: Diagnostic accuracy and clinical impact of internist-performed point-of-care ultrasound in atrial fibrillation: a multicenter study.

Internal and emergency medicine·2026
Same journal

Managing emergency department overcrowding: analysis through a dynamic simulation model of the impact of organizational variables on emergency department processes.

Internal and emergency medicine·2026
Same journal

Gunshot-induced carotid artery injury: exploring other determined aetiologies of stroke.

Internal and emergency medicine·2026
Same journal

Machine learning phenotypes and heterogeneous albumin effects in cirrhotic AKI: a causal inference study.

Internal and emergency medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

New direct thrombin inhibitors.

Alessandro Squizzato1, Francesco Dentali, Luigi Steidl

  • 1Department of Clinical Medicine, University of Insubria, Varese, Italy. alexsquizzo@libero.it

Internal and Emergency Medicine
|September 17, 2009
PubMed
Summary
This summary is machine-generated.

New direct thrombin inhibitors (DTIs) like dabigatran etexilate offer oral anticoagulation for preventing blood clots. Ongoing research assesses their broad clinical utility and safety compared to existing treatments.

Related Experiment Videos

Last Updated: Jun 20, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Direct thrombin inhibitors (DTIs) are anticoagulants targeting thrombin, a key enzyme in blood coagulation.
  • Newer generations, including dabigatran etexilate and AZD0837, are under development for enhanced anticoagulant therapy.
  • Oral administration of these novel DTIs offers potential convenience over traditional treatments.

Purpose of the Study:

  • To review the development and potential clinical applications of new direct thrombin inhibitors.
  • To highlight dabigatran etexilate's current approvals and ongoing trials for various thrombotic conditions.
  • To introduce AZD0837 and its progression into clinical development for atrial fibrillation.

Main Methods:

  • Review of preclinical and clinical data for dabigatran etexilate and AZD0837.
  • Analysis of ongoing clinical trials evaluating efficacy and safety in diverse patient populations.
  • Comparison of theoretical advantages of new DTIs over vitamin K antagonists and low molecular weight heparins.

Main Results:

  • Dabigatran etexilate is approved in the EU and Canada for VTE prevention post-hip/knee surgery.
  • Ongoing trials investigate dabigatran etexilate for VTE treatment, atrial fibrillation, and acute coronary syndromes.
  • AZD0837 is in Phase III trials for atrial fibrillation, with earlier data showing potent thrombin inhibition.

Conclusions:

  • New oral direct thrombin inhibitors represent a significant advancement in anticoagulant therapy.
  • Dabigatran etexilate shows promise across a wide spectrum of thrombotic and embolic conditions.
  • Further clinical practice data will determine the optimal use of these novel anticoagulants.